Apr 17 |
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
|
Apr 11 |
3 Pharma Stocks to Sell in April Before They Crash & Burn
|
Apr 10 |
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
|
Apr 2 |
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
|
Apr 1 |
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
|
Mar 28 |
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares
|
Mar 14 |
3 Pharma Stocks to Sell in March Before They Crash & Burn
|
Mar 13 |
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
|
Mar 13 |
Evaluating Acadia's Market Position Following Pimavanserin's Clinical Setback
|
Mar 12 |
Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
|